Director/PDMR Shareholding

Dundee, Scotland, 3 December 2009: Today, it was intimated to Axis-Shield plc that Dr Erling Sundrehagen, Chief Scientific Office, has sold 100,000 Ordinary shares of 35 pence each at a price

of 408 pence per share. After the sale, Dr Sundrehagen's beneficial interest will be 79,645 ordinary shares, 153,800 long term incentive plan award shares and 402,500 medium term share options.

This announcement requires to be made on the London Stock Exchange and is repeated in Norway for Oslo Stock Exchange purposes in accordance with the 'equivalent information' rule (Rule DTR 2.4).

Enquiries:

Notes to Editors:

About Axis-Shield

Axis-Shield is an international in vitro diagnostics company, headquartered in Dundee with R&D and manufacturing bases in Dundee and Oslo. The Group specialises in the supply of instruments and tests for the rapidly growing physician's office testing market and the development, manufacture and marketing of innovative proprietary diagnostics kits in areas of clinical need, including cardiovascular and neurological diseases, rheumatoid arthritis, and diabetes.

For more information on Axis-Shield, please refer to www.axis-shield.com